FindMyKOL
Clinical trialNCT07838649Not, yet, recruitingPhase 1Interventional

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

NCT07838649 is a phase 1 interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is not yet recruiting. It studies Fluorodeoxyglucose F18 and 68Ga-Galmydar in Breast Cancer, Cancer of the Breast and 3 more conditions. The registry lists an enrollment of 36 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2026 and a primary completion date of 12 Dec 2029. One of its registered investigators has a FindMyKOL profile.

SponsorWashington University School of Medicine →Enrollment36Breast CancerCancer of the BreastHodgkin LymphomaLymphoma CancerNon-Hodgkin Lymphoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07838649
FieldValue
Registry IDNCT07838649
StatusNot yet recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorWashington University School of Medicine
Enrollment36
Registered sites1
Countries1
ConditionsBreast Cancer, Cancer of the Breast, Hodgkin Lymphoma, Lymphoma Cancer and Non-Hodgkin Lymphoma
DrugsFluorodeoxyglucose F18 and 68Ga-Galmydar
Start1 Nov 2026
Primary completion12 Dec 2029
Study completion12 Dec 2029
Last update posted24 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Missouri, United States1 site
  • Washington University School of Medicine

    St Louis

    Cynthia Ma, MD, PhDJie Zheng, PhDJoshua D Mitchell, MDKatherine N Weilbaecher, MDNeha Mehta-Shah, MDPamela K Woodard, MDRichard Laforest, PhDThomas H Schindler, MDVijay Sharma, PhDYan Yan, MD

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 siteMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Fluorodeoxyglucose F1868Ga-Galmydar
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07838649

Each answer restates registry values shown on this page.

What is NCT07838649?

NCT07838649 is a phase 1 interventional trial sponsored by Washington University School of Medicine. It studies Fluorodeoxyglucose F18 and 68Ga-Galmydar in Breast Cancer, Cancer of the Breast and 3 more conditions.

Is NCT07838649 recruiting?

As of 21 Nov 2026, it is not yet recruiting.

Who leads NCT07838649?

The registry names Pamela K Woodard, MD (principal investigator, Washington University School of Medicine) as the overall official.

Where does NCT07838649 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07838649 study?

The registered drug and biological interventions are Fluorodeoxyglucose F18 and 68Ga-Galmydar.

When is NCT07838649 expected to complete?

The registry lists a primary completion date of 12 Dec 2029 and a study completion date of 12 Dec 2029. The sponsor last updated the record on 24 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.